Have a personal or library account? Click to login
Implications of Evolving Medical Science for Proof of Lung Cancer Causation Cover

Implications of Evolving Medical Science for Proof of Lung Cancer Causation

Open Access
|Oct 2015

References

  1. 1. Hanahan, D. and R.A. Weinberg: The Hallmarks of Cancer; Cell 100 (2000) 57-70.
  2. 2. Vogelstein, B., N. Papadopoulos, V.E. Velculescu, S. Zhou, L.A. Diaz, Jr, and K.W. Kinzler: Cancer Genome Landscapes; Science 339 (2013) 1546-1558.
  3. 3. Raparia, K., C. Villa, M.M. DeCamp, J.D. Patel, and M.P. Mehta: Molecular Profiling in Non-Small Cell Lung Cancer: A Step Toward Personalized Medicine; Arch. Pathol. Lab. Med. 137 (2013) 481-491.
  4. 4. Rosai, J.: Rosai and Ackerman’s Surgical Pathology, 9th ed., Mosby, Edinburgh, UK, 2004.
  5. 5. Coolidge v. Philip Morris Inc., RIC361063 Superior Court of California, Riverside County, Dept. 6 (2005).
  6. 6. Khuder, S.A.: Effect of Cigarette Smoking on Major Histological Types of Lung Cancer: A Meta-Analysis; Lung Cancer 31 (2001) 139-148.
  7. 7. Rudin, C.M., E. Avila-Tang, C.C. Harris, J.G. Herman, F.R. Hirsch, W. Pao, A.G. Schwartz, K.H. Vahakangas, and J.M. Samet: Lung Cancer in Never Smokers: Molecular Profiles and Therapeutic Implications; Clin.Cancer Res. 15 (2009) 5646-5661.
  8. 8. Pesch, B., B. Kendzia, P. Gustavsson, K.-H. Jöckel, G.Johnen, H. Pohlabeln, A. Olsson, W. Ahrens, I.M.Gross, I. Brüske, H.-E. Wichmann, F. Merletti, L.Richiardi, L. Simonato, C. Fortes, J. Siemiatycki, M.-E.Parent, D. Consonni, M.T. Landi, N. Caporaso, D.Zaridze, A. Cassidy, N. Szeszenia-Dabrowska, P. Rudnai, J. Lissowska, I. Stücker, E. Fabianova, R.S.Dumitru, V. Bencko, L. Foretova, V. Janout, C.M.Rudin, P. Brennan, P. Boffetta, K. Straif, and T.Brüning: Cigarette Smoking and Lung Cancer- Relative Risk Estimates for the Major Histological Types from a Pooled Analysis of Case-Control Studies; Int. J. Cancer 131 (2012) 1210-1219.
  9. 9. Devesa, S.S., F. Bray, A.P. Vizcaino, and D.M. Parkin: International Lung Cancer Trends by Histologic Type: Male:Female Differences Diminishing and Adeno- carcinoma Rates Rising; Int. J. Cancer 117 (2005) 294-299.
  10. 10. Doll, R., A.B. Hill, and L. Kreyberg: The Significance of Cell Type in Relation to the Aetiology of Lung Cancer; Br. J. Cancer 11 (1957) 43-48.
  11. 11. Travis, W.D., E. Brambilla, M. Noguchi, A.G. Nicholson, K.R. Geisinger, Y. Yatabe, D.G. Beer, C.A. Powell, G.J. Riely, P.E. Van Schil, K. Garg, J.H.M Austin, H. Asamura, V.W. Rusch, F.R. Hirsch, G. Scagliotti, T. Mitsudomi, R.M. Huber, Y. Ishikawa, J.Jett, M. Sanchez-Cespedes, J.-P. Sculier, T. Takahashi, M. Tsuboi, J. Vansteenkiste, I.I. Wistuba, P.-C. Yang, D. Aberle, C. Brambilla, D. Flieder, W. Franklin, A. Gazdar, M. Gould, P. Hasleton, D. Henderson, B.Johnson, D. Johnson, K. Kerr, K. Kuriyama, J.S. Lee, V.A. Miller, I. Petersen, V. Roggli, R. Rosell, N. Saijo, E. Thunnissen, M. Tsao, and D. Yankelewitz: International Association for the Study of Lung Cancer/ American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma; J. Thorac. Oncol. 6 (2011) 244-285.
  12. 12. Thun, M.J., C.A. Lally, J.T. Flannery, E.E. Calle, W.D. Flanders, and C.W. Heath, Jr: Cigarette Smoking and Changes in the Histopathology of Lung Cancer; J. Natl. Cancer Inst. 89 (1997) 1580-1586.
  13. 13. Burns, D.M., C.M. Anderson, and N. Gray: Do Changes in Cigarette Design Influence the Rise in Adenocarcinoma of the Lung?; Cancer Causes Control 22 (2011) 13-22.
  14. 14. Brooks, D.R., J.H.M. Austin, R.T. Heelan, M.S. Ginsberg, V. Shin, S.H. Olson, J.E. Muscat, and S.D. Stellman: Influence of Type of Cigarette on Peripheral versus Central Lung Cancer; Cancer Epidemiol. Biomarkers Prev. 14 (2005) 576-581.
  15. 15. Chen, F., P. Cole, and W.F. Bina: Time Trend and Geographic Patterns of Lung Adenocarcinoma in the United States, 1973-2002; Cancer Epidemiol. Biomarkers Prev. 16 (2007) 2724-2729.
  16. 16. Fry, J.S., P.N. Lee, B.A. Forey, and K.J. Coombs: Is The Shape of the Decline in Risk Following Quitting Smoking Similar for Squamous Cell Carcinoma and Adenocarcinoma of the Lung? A Quantitative Review Using The Negative Exponential Model; Regul. Toxicol. Pharmacol. 72 (2015) 49-57.
  17. 17. Simonato, L., A. Agudo, W. Ahrens, E. Benhamou, S. Benhamou, P. Boffetta, P. Brennan, S.C. Darby, F. Forastiere, C. Fortes, V. Gaborieau, M. Gerken, C.A. Gonzales, K.-H. Jöckel, M. Kreuzer, F. Merletti, F. Nyberg, G. Pershagen, H. Pohlabeln, F. Rösch, E. Whitley, H.-E. Wichmann, and P. Zambon: Lung Cancer and Cigarette Smoking in Europe: An Update of Risk Estimates and an Assessment of Inter-Country Heterogeneity; Int. J. Cancer 91 (2001) 876-887.
  18. 18. Vogelstein, B. and K.W. Kinzler: Cancer Genes and the Pathways they Control; Nat. Med. 10 (2004) 789-799.
  19. 19. Vineis, P. and D. Kriebel: Causal Models in Epidemiology: Past Inheritance and Genetic Future; Environ. Health 5 (2006) 21.
  20. 20. Kerr, K.M.: Clinical Relevance of the New IASLC / ERS / ATS Adenocarcinoma Classification; J. Clin. Pathol. 66 (2013) 832-838.
  21. 21. Mundt, K.A., C. Bigelow, and E. van Wijngaarden: Apportionment of Disease in Individuals; J. Clin. Epidemiol. 56 (2003) 290-291; author reply 291.10.1016/S0895-4356(02)00594-2
  22. 22. Rothman, K.J. and S. Greenland: Causation and Causal Inference in Epidemiology; Am. J. Public Health 95 Suppl 1 (2005) S144-150.10.2105/AJPH.2004.05920416030331
  23. 23. Greenland, S. and J.M. Robins: Epidemiology, Justice, and the Probability of Causation; Jurimetrics 40 (2000) 321-340.
  24. 24. Peto, R., S. Darby, H. Deo, P. Silcocks, E. Whitley, and R. Doll: Smoking, Smoking Cessation, and Lung Cancer in the UK since 1950: Combination of National Statistics with Two Case-Control Studies; BMJ 321 (2000) 323-329.
  25. 25. International Agency for Research on Cancer (IARC): Tobacco Control: Reversal of Risk After Quitting Smoking; IARC Handbooks of Cancer Prevention, Volume 11, IARC Press, Lyon, France, 2007.
  26. 26. Doll, R., R. Peto, J. Boreham, and I. Sutherland: Mortality in Relation to Smoking: 50 Years’ Observations on Male British Doctors; BMJ 328 (2004) 1519.
  27. 27. Khuder, S.A. and A.B. Mutgi: Effect of Smoking Cessation on Major Histologic Types of Lung Cancer; Chest 120 (2001) 1577-1583.
  28. 28. Speizer, F.E., G.A. Colditz, D.J. Hunter, B. Rosner, and C. Hennekens: Prospective Study of Smoking, Antioxidant Intake, and Lung Cancer in Middle-Aged Women (USA); Cancer Causes Control 10 (1999) 475-482.
  29. 29. Ebbert, J.O., P. Yang, C.M. Vachon, R.A. Vierkant, J.R. Cerhan, A.R. Folsom, and T.A. Sellers: Lung Cancer Risk Reduction After Smoking Cessation: Observations from a Prospective Cohort of Women; J. Clin. Oncol. 21 (2003) 921-926.
  30. 30. Flanders, W.D., C.A. Lally, B.-P. Zhu, S.J. Henley, and M.J. Thun: Lung Cancer Mortality in Relation to Age, Duration of Smoking, and Daily Cigarette Consumption: Results from Cancer Prevention Study II; Cancer Res. 63 (2003) 6556-6562.
  31. 31. Lubin, J.H. and N.E. Caporaso: Cigarette Smoking and Lung Cancer: Modeling Total Exposure and Intensity; Cancer Epidemiol. Biomarkers Prev. 15 (2006) 517-523.
  32. 32. Govindan, R., L. Ding, M. Griffith, J. Subramanian, N.D. Dees, K.L. Kanchi, C.A. Maher, R. Fulton, L. Fulton, J. Wallis, K. Chen, J. Walker, S. McDonald, R. Bose, D. Ornitz, D. Xiong, M. You, D.J. Dooling, M. Watson, E.R. Mardis, and R.K. Wilson: Genomic Landscape of Non-Small Cell Lung Cancer in Smokers and Never-Smokers; Cell 150 (2012) 1121-1134.
  33. 33. Li, F., Y. Feng, R. Fang, Z. Fang, J. Xia, X. Han, X.-Y. Liu, H. Chen, H. Liu, and H. Ji: Identification of RET Gene Fusion by Exon Array Analyses in "Pan-Negative" Lung Cancer from Never Smokers; Cell Res. 22 (2012) 928-931.
  34. 34. Sun, S., J.H. Schiller, and A.F. Gazdar: Lung Cancer in Never Smokers--A Different Disease; Nat. Rev. Cancer 7 (2007) 778-790.
  35. 35. Ou, S.-H.: Lung Cancer in Never-Smokers. Does Smoking History Matter in the Era of Molecular Diagnostics and Targeted Therapy?; J. Clin. Pathol. 66 (2013) 839-846.
  36. 36. Staaf, J., G. Jönsson, M. Jönsson, A. Karlsson, S. Isaksson, A. Salomonsson, H.M. Pettersson, M. Soller, S.B. Ewers, L. Johansson, P. Jönsson, and M. Planck: Relation between Smoking History and Gene Expression Profiles in Lung Adenocarcinomas; BMC Med Genomics 5 (2012) 22.
  37. 37. Noguchi, M., A. Morikawa, M. Kawasaki, Y. Matsuno, T. Yamada, S. Hirohashi, H. Kondo, and Y. Shimosato: Small Adenocarcinoma of the Lung. Histologic Characteristics and Prognosis; Cancer 75 (1995) 2844-2852.
  38. 38. Colby, T., M. Noguchi, and C. Henschke: Adenocarcinoma; in: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart; 3rd ed., edited by W.B. Travis, E. Brambilla, H.K. Müller-Hermlink, and C.C. Harris, International Agency for Research on Cancer, Lyon, France, 2004, pp 35-44.
  39. 39. Motoi, N., J. Szoke, G.J. Riely, V.E. Seshan, M.G. Kris, V.W. Rusch, W.L. Gerald, and W.D. Travis: Lung Adenocarcinoma: Modification of the 2004 WHO Mixed Subtype to Include the Major Histologic Subtype Suggests Correlations between Papillary and Micropapillary Adenocarcinoma Subtypes, EGFR Mutations and Gene Expression Analysis; Am. J. Surg. Pathol. 32 (2008) 810-827.
  40. 40. Nassar, H.: Carcinomas with Micropapillary Morphology: Clinical Significance and Current Concepts; Adv. Anat. Pathol. 11 (2004) 297-303.
  41. 41. Rekhtman, N., P.K. Paik, M.E. Arcila, L.J. Tafe, G.R. Oxnard, A.L. Moreira, W.D. Travis, M.F. Zakowski, M.G. Kris, and M. Ladanyi: Clarifying the Spectrum of Driver Oncogene Mutations in Biomarker-Verified Squamous Carcinoma of Lung: Lack of EGFR/KRAS and Presence of PIK3CA/AKT1 Mutations; Clin. Cancer Res. 18 (2012) 1167-1176.
  42. 42. Dogan, S., R. Shen, D.C. Ang, M.L. Johnson, S.P. D’Angelo, P.K. Paik, E.B. Brzostowski, G.J. Riely, M.G. Kris, M.F. Zakowski, and M. Ladanyi: Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS-Mutant Cancers; Clin. Cancer Res. 18 (2012) 6169-6177.
  43. 43. Girard, N., C.S. Sima, D.M. Jackman, L.V. Sequist, H. Chen, J.C.-H. Yang, H. Ji, B. Waltman, R. Rosell, M. Taron, M.F. Zakowski, M. Ladanyi, G. Riely, and W. Pao: Nomogram to Predict the Presence of EGFR Activating Mutation in Lung Adenocarcinoma; Eur. Respir. J. 39 (2012) 366-372.
  44. 44. Imielinski, M., A.H. Berger, P.S. Hammerman, B. Hernandez, T.J. Pugh, E. Hodis, J. Cho, J. Suh, M. Capelletti, A. Sivachenko, C. Sougnez, D. Auclair, M.S. Lawrence, P. Stojanov, K. Cibulskis, K. Choi, L. de Waal, T. Sharifnia, A. Brooks, H. Greulich, S.Banerji, T. Zander, D. Seidel, F. Leenders, S. Ansén, C.Ludwig, W. Engel-Riedel, E. Stoelben, J. Wolf, C. Goparju, K. Thompson, W. Winckler, D. Kwiatkowski, B.E. Johnson, P.A. Jänne, V.A. Miller, W. Pao, W.D. Travis, H.I. Pass, S.B. Gabriel, E.S. Lander, R.K. Thomas, L.A. Garraway, G. Getz, and M. Meyerson: Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing; Cell 150 (2012) 1107-1120.
  45. 45. Kris, M.G., B.E. Johnson, L.D. Berry, D.J. Kwiat Kwiatkowski, A.J. Iafrate, I.I. Wistuba, M. Varella-Garcia, W.A. Franklin, S.L. Aronson, P.-F. Su, Y. Shyr, D.R. Camidge, L.V. Sequist, B.S. Glisson, F.R. Khuri, E.B. Garon, W. Pao, C. Rudin, J. Schiller, E.B. Haura, M. Socinski, K. Shirai, H. Chen, G. Giaccone, M. Ladanyi, K. Kugler, J.D. Minna, and P.A. Bunn: Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs; JAMA 311 (2014) 1998-2006.
  46. 46. Lindeman, N.I., P.T. Cagle, M.B. Beasley, D.A. Chitale, S. Dacic, G. Giaccone, R.B. Jenkins, D.J. Kwiatkowski, J.-S. Saldivar, J. Squire, E. Thunnissen, and M. Ladanyi: Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology; Arch. Pathol. Lab. Med. 137 (2013) 828-860.
  47. 47. Shigematsu, H., L. Lin, T. Takahashi, M. Nomura, M. Suzuki, I.I. Wistuba, K.M. Fong, H. Lee, S. Toyooka, N. Shimizu, T. Fujisawa, Z. Feng, J.A. Roth, J. Herz, J.D. Minna, and A.F. Gazdar: Clinical and Biological Features Associated with Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers; J. Natl. Cancer Inst. 97 (2005) 339-346.
  48. 48. Kim, H.R., J.R. Ahn, J.G. Lee, D.H. Bang, S.-J. Ha, Y.K. Hong, S.M. Kim, K.C. Nam, S.Y. Rha, R.A. Soo, G.J. Riely, J.H. Kim, and B.C. Cho: The Impact of Cigarette Smoking on the Frequency of and Qualitative Differences in KRAS Mutations in Korean Patients with Lung Adenocarcinoma; Yonsei Med. J. 54 (2013) 865-874.
  49. 49. Kim, H.R., H.S. Shim, J.-H. Chung, Y.J. Lee, Y.K. Hong, S.Y. Rha, S.H. Kim, S.-J. Ha, S.K. Kim, K.Y. Chung, R. Soo, J.H. Kim, and B.C. Cho: Distinct Clinical Features and Outcomes in Never-Smokers with Nonsmall Cell Lung Lancer who Harbor EGFR or KRAS Mutations or ALK rearrangement; Cancer 118 (2012) 729-739.
  50. 50. Riely, G.J., M.G. Kris, D. Rosenbaum, J. Marks, A. Li, D.A. Chitale, K. Nafa, E.R. Riedel, M. Hsu, W. Pao, V.A. Miller, and M. Ladanyi: Frequency and Distinctive Spectrum of KRAS Mutations in Never Smokers with Lung Adenocarcinoma; Clin. Cancer Res. 14 (2008) 5731-5734.
  51. 51. Riely, G.J., J. Marks, and W. Pao: KRAS Mutations in Non-Small Cell Lung Cancer; Proc. Am. Thorac. Soc. 6 (2009) 201-205.
  52. 52. Smits, A.J.J., J.A. Kummer, J.W.J. Hinrichs, G.J.M. Herder, K.C. Scheidel-Jacobse, N.M. Jiwa, T.E.G. Ruijter, P.T.G.A. Nooijen, M.G. Looijen-Salamon, M.J.L. Ligtenberg, F.B. Thunnissen, D.A.M. Heideman, R.A. de Weger, and A. Vink: EGFR and KRAS Mutations in Lung Carcinomas in the Dutch Population: Increased EGFR Mutation Frequency in Malignant Pleural Effusion of Lung Adenocarcinoma; Cell. Oncol. 35 (2012) 189-196.
  53. 53. Cardarella, S., A. Ogino, M. Nishino, M. Butaney, J. Shen, C. Lydon, B.Y. Yeap, L.M. Sholl, B.E. Johnson, and P.A. Jänne: Clinical, Pathologic, and Biologic Features Associated with BRAF Mutations in Non- Small Cell Lung Cancer; Clin. Cancer Res. 19 (2013) 4532-4540.
  54. 54. Marchetti, A., L. Felicioni, S. Malatesta, M. Grazia Sciarrotta, L. Guetti, A. Chella, P. Viola, C. Pullara, F. Mucilli, and F. Buttitta: Clinical Features and Outcome of Patients with Non-Small-Cell Lung Cancer Harboring BRAF Mutations; J. Clin. Oncol. 29 (2011) 3574-3579.
  55. 55. Paik, P.K., M.E. Arcila, M. Fara, C.S. Sima, V.A. Miller, M.G. Kris, M. Ladanyi, and G.J. Riely: Clinical Characteristics of Patients with Lung Adenocarcinomas Harboring BRAF Mutations; J. Clin. Oncol. 29 (2011) 2046-2051.
  56. 56. Sasaki, H., M. Shitara, K. Yokota, K. Okuda, Y. Hikosaka, S. Moriyama, M. Yano, and Y. Fujii: Braf and erbB2 Mutations Correlate with Smoking Status in Lung Cancer Patients; Exp. Ther. Med. 3 (2012) 771-775.
  57. 57. Arcila, M.E., J.E. Chaft, K. Nafa, S. Roy-Chowdhuri, C. Lau, M. Zaidinski, P.K. Paik, M.F. Zakowski, M.G. Kris, and M. Ladanyi: Prevalence, Clinicopathologic Associations, and Molecular Spectrum of ERBB2 (HER2) Tyrosine Kinase Mutations in Lung Adenocarcinomas; Clin. Cancer Res. 18 (2012) 4910-4918.
  58. 58. Mazières, J., S. Peters, B. Lepage, A.B. Cortot, F. Barlesi, M. Beau-Faller, B. Besse, H. Blons, A. Mansuet-Lupo, T. Urban, D. Moro-Sibilot, E. Dansin, C. Chouaid, M. Wislez, J. Diebold, E. Felip, I. Rouquette, J.D. Milia, and O. Gautschi: Lung Cancer that Harbors a HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives; J. Clin. Oncol. 31 (2013) 1997-2003.
  59. 59. Shigematsu, H., T. Takahashi, M. Nomura, K. Majmudar, M. Suzuki, H. Lee, I.I. Wistuba, K.M. Fong, S. Toyooka, N. Shimizu, T. Fujisawa, J.D. Minna, and A.F. Gazdar: Somatic Mutations of the HER2 Kinase Domain in Lung Adenocarcinomas; Cancer Res. 65 (2005) 1642-1646.
  60. 60. Sonobe, M., T. Manabe, H. Wada, and F. Tanaka: Lung Adenocarcinoma Harboring Mutations in the ERBB2 Kinase Domain; J. Mol. Diagn. 8 (2006) 351-356.
  61. 61. Bergethon, K., A.T. Shaw, S.-H.I. Ou, R. Katayama, C.M. Lovly, N.T. McDonald, P.P. Massion, C. Siwak- Tapp, A. Gonzalez, R. Fang, E.J. Mark, J.M. Batten, H. Chen, K.D. Wilner, E.L. Kwak, J.W. Clark, D.P. Carbone, H. Ji, J.A. Engelman, M. Mino-Kenudson, W. Pao, and A.J. Iafrate: ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers; J. Clin. Oncol. 30 (2012) 863-870.
  62. 62. Cha, Y.J., J.S. Lee, H.R. Kim, S.M. Lim, B.C. Cho, C.Y. Lee, and H.S. Shim: Screening of ROS1 Rearrangements in Lung Adenocarcinoma by Immunohistochemistry and Comparison with ALK Rearrangements; PLoS ONE 9 (2014) e103333.
  63. 63. Shan, L., F. Lian, L. Guo, T. Qiu, Y. Ling, J. Ying, and D. Lin: Detection of ROS1 Gene Rearrangement in Lung Adenocarcinoma: Comparison of IHC, FISH and Real-Time RT-PCR; PLoS ONE 10 (2015) e0120422.
  64. 64. Lee, S.E., B. Lee, M. Hong, J.-Y. Song, K. Jung, M.E. Lira, M. Mao, J. Han, J. Kim, and Y.L. Choi: Comprehensive Analysis of RET and ROS1 Rearrangement in Lung Adenocarcinoma; Mod. Pathol. 28 (2015) 468-479.
  65. 65. Yokota, K., H. Sasaki, K. Okuda, S. Shimizu, M. Shitara, Y. Hikosaka, S. Moriyama, M. Yano, and Y. Fujii: KIF5B/RET Fusion Gene in Surgically-Treated Adenocarcinoma of the Lung; Oncol. Rep. 28 (2012) 1187-1192.
  66. 66. Kim, H. and J.-H. Chung: Overview of Clinicopathologic Features of ALK-Rearranged Lung Adenocarcinoma and Current Diagnostic Testing for ALK Rearrangement; Transl. Lung Cancer Res. 4 (2015) 149-155.
  67. 67. Koh, Y., D.-W. Kim, T.M. Kim, S.-H. Lee, Y.K. Jeon, D.H. Chung, Y.-W. Kim, D.S. Heo, W.-H. Kim, and Y.-J. Bang: Clinicopathologic Characteristics and Outcomes of Patients with Anaplastic Lymphoma Kinase- Positive Advanced Pulmonary Adenocarcinoma: Suggestion for an Effective Screening Strategy for these Tumors; J. Thorac. Oncol. 6 (2011) 905-912.
  68. 68. Li, Y., Y. Li, T. Yang, S. Wei, J. Wang, M. Wang, Y. Wang, Q. Zhou, H. Liu, and J. Chen: Clinical Significance of EML4-ALK Fusion Gene and Association with EGFR and KRAS Gene Mutations in 208 Chinese Patients with Non-Small Cell Lung Cancer; PLoS ONE 8 (2013) e52093.
  69. 69. Oxnard, G.R., K.-S. Nguyen, and D.B. Costa: Germline Mutations in Driver Oncogenes and Inherited Lung Cancer Risk Independent of Smoking History; J. Natl. Cancer Inst. 106 (2014) djt361.10.1093/jnci/djt36124317178
  70. 70. Wang, Y., S. Wang, S. Xu, J. Qu, and B. Liu: Clinicopathologic Features of Patients with Non-Small Cell Lung Cancer Harboring the EML4-ALK Fusion Gene: A Meta-Analysis; PLoS ONE 9 (2014) e110617.
  71. 71. Lynch, T.J., D.W. Bell, R. Sordella, S. Gurubhagavatula, R.A. Okimoto, B.W. Brannigan, P.L. Harris, S.M. Haserlat, J.G. Supko, F.G. Haluska, D.N. Louis, D.C. Christiani, J. Settleman, and D.A. Haber: Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non-Small- Cell Lung Cancer to Gefitinib; N. Engl. J. Med. 350 (2004) 2129-2139.
  72. 72. Paez, J.G., P.A. Jänne, J.C. Lee, S. Tracy, H. Greulich, S. Gabriel, P. Herman, F.J. Kaye, N. Lindeman, T.J. Boggon, K. Naoki, H. Sasaki, Y. Fujii, M.J. Eck, W.R. Sellers, B.E. Johnson, and M. Meyerson: EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy; Science 304 (2004) 1497-1500.
  73. 73. Pao, W., V. Miller, M. Zakowski, J. Doherty, K. Politi, I. Sarkaria, B. Singh, R. Heelan, V. Rusch, L. Fulton, E. Mardis, D. Kupfer, R. Wilson, M. Kris, and H. Varmus: EGF Receptor Gene Mutations are Common in Lung Cancers from "Never Smokers" and are Associated with Sensitivity of Tumors to Gefitinib and Erlotinib; Proc. Natl. Acad. Sci. U S A 101 (2004) 13306-13311.
  74. 74. D’Angelo, S.P., M.C. Pietanza, M.L. Johnson, G.J. Riely, V.A. Miller, C.S. Sima, M.F. Zakowski, V.W. Rusch, M. Ladanyi, and M.G. Kris: Incidence of EGFR Exon 19 Deletions and L858R in Tumor Specimens from Men and Cigarette Smokers with Lung Adenocarcinomas; Clin. Oncol. 29 (2011) 2066-2070.
  75. 75. Thu, K.L., E.A. Vucic, R. Chari, W. Zhang, W.W. Lockwood, J.C. English, R. Fu, P. Wang, Z. Feng, C.E. MacAulay, .F. Gazdar, S. Lam, and W.L. Lam: Lung Adenocarcinoma of Never Smokers and Smokers Harbor Differential Regions of Genetic Alteration and Exhibit Different Levels of Genomic Instability; PLoS ONE 7 (2012) e33003.
  76. 76. Leary, A.F., D. Gonsalez de Castro, A.G. Nicholson, S. Ashley, A. Wotherspoon, M.E.R. O’Brien, and S. Popat: Establishing an EGFR Mutation Screening Service for Non-Small Cell Lung Cancer - Sample Quality Criteria and Candidate Histological Predictors; Eur. J. Cancer 48 (2012) 61-67.
  77. 77. Li, H., Y. Pan, Y. Li, C. Li, R. Wang, H. Hu, Y. Zhang, T. Ye, L. Wang, L. Shen, Y. Sun, and H. Chen: Frequency of Well-Identified Oncogenic Driver Mutations in Lung Adenocarcinoma of Smokers Varies with Histological Subtypes and Graduated Smoking Dose; Lung Cancer 79 (2013) 8-13.
  78. 78. Jänne, P.A., A.T. Shaw, J.R. Pereira, G. Jeannin, J. Vansteenkiste, C. Barrios, F.A. Franke, L. Grinsted, V. Zazulina, P. Smith, I. Smith, and L. Crinò: Selumetinib plus Docetaxel for KRAS-Mutant Advanced Non- Small-Cell Lung Cancer: A Randomised, Multicentre, Placebo-Controlled, Phase 2 Study; Lancet Oncol. 14 (2013) 38-47.
  79. 79. Tsuta, K., M. Kawago, E. Inoue, A. Yoshida, F. Takahashi, H. Sakurai, S.-I. Watanabe, M. Takeuchi, K. Furuta, H. Asamura, and H. Tsuda: The Utility of the Proposed IASLC/ATS/ERS Lung Adenocarcinoma Subtypes for Disease Prognosis and Correlation of Driver Gene Alterations; Lung Cancer 81 (2013) 371-376.
  80. 80. Maeda, R., G. Ishii, J. Yoshida, T. Hishida, M. Nishimura, and K. Nagai: Influence of Cigarette Smoking on Histological Subtypes of Stage I Lung Adenocarcinoma; J. Thorac. Oncol. 6 (2011) 743-750.
  81. 81. Sakao, Y., H. Miyamoto, S. Oh, N. Takahashi, T.Inagaki, Y. Miyasaka, T. Akaboshi, and M. Sakuraba: The Impact of Cigarette Smoking on Prognosis in Small Adenocarcinomas of the Lung: The Association between Histologic Subtype and Smoking Status; J.Thorac. Oncol. 3 (2008) 958-962.
  82. 82. Hu, H., Y. Pan, Y. Li, L. Wang, R. Wang, Y. Zhang, H. Li, T. Ye, Y. Zhang, X. Luo, L. Shao, Z. Sun, D. Cai, J. Xu, Q. Lu, Y. Deng, L. Shen, H. Ji, Y. Sun, and H. Chen: Oncogenic Mutations Are Associated with Histological Subtypes but do Not Have an Independent Prognostic Value in Lung Adenocarcinoma; Onco. Targets Ther. 7 (2014) 1423-1437.
  83. 83. Miyoshi, T., Y. Satoh, S. Okumura, K. Nakagawa, T. Shirakusa, E. Tsuchiya, and Y. Ishikawa: Early-Stage Lung Adenocarcinomas with a Micropapillary Pattern, a Distinct Pathologic Marker for a Significantly Poor Prognosis; Am. J. Surg. Pathol. 27 (2003) 101-109.
  84. 84. Villa, C., P.T. Cagle, M. Johnson, J.D. Patel, A.V. Yeldandi, R. Raj, M.M. DeCamp, and K. Raparia: Correlation of EGFR Mutation Status with Predominant Histologic Subtype of Adenocarcinoma According to the New Lung Adenocarcinoma Classification of the International Association for the Study of Lung Cancer/ American Thoracic Society/European Respiratory Society; Arch. Pathol. Lab. Med. 138 (2014) 1353-1357.
  85. 85. An, S.-J., Z.-H. Chen, J. Su, X.-C. Zhang, W.-Z. Zhong, J.-J. Yang, Q. Zhou, X.-N. Yang, L. Huang, J.- L. Guan, Q. Nie, H.-H. Yan, T.S. Mok, and Y.-L. Wu: Identification of Enriched Driver Gene Alterations in Subgroups of Non-Small Cell Lung Cancer Patients Based on Histology and Smoking Status; PLoS ONE 7 (2012) e40109.
  86. 86. Huang, S.-F., H.-P. Liu, L.-H. Li, Y.-C. Ku, Y.-N. Fu, H.-Y. Tsai, Y.-T. Chen, Y.-F. Lin, W.-C. Chang, H.-P. Kuo, Y.-C. Wu, Y.-R. Chen, and S.-F. Tsai: High Frequency of Epidermal Growth Factor Receptor Mutations with Complex Patterns in Non-Small Cell Lung Cancers Related to Gefitinib Responsiveness in Taiwan; Clin. Cancer Res. 10 (2004) 8195-8203.
  87. 87. Yano, T., A. Haro, Y. Shikada, R. Maruyama, and Y. Maehara: Non-Small Cell Lung Cancer in Never Smokers as a Representative ’Non-Smoking-Associated Lung Cancer’: Epidemiology and Clinical Features; Int. J. Clin. Oncol. 16 (2011) 287-293.
  88. 88. Paik, P.K., M.L. Johnson, S.P. D’Angelo, C.S. Sima, D. Ang, S. Dogan, V.A. Miller, M. Ladanyi, M.G. Kris, and G.J. Riely: Driver Mutations Determine Survival in Smokers and Never-Smokers with Stage IIIB/IV Lung Adenocarcinomas; Cancer 118 (2012) 5840-5847.
  89. 89. Karlsson, A., M. Ringnér, M. Lauss, J. Botling, P. Micke, M. Planck, and J. Staaf: Genomic and Transcriptional Alterations in Lung Adenocarcinoma in Relation to Smoking History; Clin. Cancer Res. 20 (2014) 4912-4924.
  90. 90. Krishnan, V.G., P.J. Ebert, J.C. Ting, E. Lim, S.-S. Wong, A.S.M. Teo, Y.G. Yue, H.-H. Chua, X. Ma, G.S.L. Loh, Y. Lin, J.H.J. Tan, K. Yu, S. Zhang, C.Reinhard, D.S.W. Tan, B.A. Peters, S.E. Lincoln, D.G.Ballinger, J.M. Laramie, G.B. Nilsen, T.D. Barber, P.Tan, A.M. Hillmer, and P.C. Ng: Whole-Genome Sequencing of Asian Lung Cancers: Second-Hand Smoke Unlikely to be Responsible for Higher Incidence of Lung Cancer Among Asian Never-Smokers; Cancer Res. 74 (2014) 6071-6081.
  91. 91. Tomashefski, J.F., Jr, P.T. Cagle, C.F. Farver, and A.E. Fraire: Dail and Hammar’s Pulmonary Pathology, Vol. II, Neoplastic Lung Disease, 3rd ed.; Springer, New York, NY, 2010.
  92. 92. Sato, S., N. Motoi, M. Hiramatsu, E. Miyauchi, H.
  93. Ono, Y. Saito, H. Nagano, H. Ninomiya, K. Inamura, H. Uehara, M. Mun, Y. Sakao, S. Okumura, M. Tsuchida, and Y. Ishikawa: Pulmonary Adenocarcinoma in Situ: Analyses of a Large Series with Reference to Smoking, Driver Mutations, and Receptor Tyrosine Kinase Pathway Activation; Am. J. Surg. Pathol. 39 (2015) 912-921.
Language: English
Page range: 298 - 311
Submitted on: Apr 9, 2014
Accepted on: Aug 26, 2015
Published on: Oct 20, 2015
Published by: Institut für Tabakforschung GmbH
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2015 Larry C. Frarey, Javier Martinez, published by Institut für Tabakforschung GmbH
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.